Eli Lilly (LLY +3.90%) had a fine start to the trading week. On Monday, its stock rose by almost 4% on news that a key European regulator had approved one of its star medications. That also provided plenty of optimism for these types of drugs, which have been hotly popular for years now.
The popular pill
The product in question is Lilly's Foundayo, its first weight-loss pill (not to be confused with the company's Zepbound, an obesity treatment delivered via injection). On Monday, the U.K.'s Medicines and Healthcare products Regulatory Agency (MHRA) approved Foundayo for both weight management and type 2 diabetes.
Image source: Getty Images.
This made the U.K. the first European nation to green-light the pill for commercialization.
As in the U.S., however, Foundayo won't be the first weight-loss pill on that market. Similarly, the Wegovy pill from pharmaceutical industry rival Novo Nordisk is currently available to British patients; this was approved by the MHRA in June.
NYSE: LLY
Key Data Points
Big prizes for No. 2
While it's always a great advantage to be a first mover, I don't think Lilly will suffer much from finishing second in the race.
First, with its massive commercial infrastructure, it can allocate considerable resources to marketing its pill to local consumers. Second, the demand for obesity treatments is so strong that even a distant second-place developer can earn considerable sales in the U.K., with its population of nearly 60 million.
Finally, this is only Lilly's first approval in Europe, a vast market. Although the continent has less of a problem with obesity than the U.S., there is still quite a large addressable population of would-be patients.
With its size and sprawl, Lilly isn't only about weight-loss drugs. Regardless, this is an unambiguously positive development in this sustainably hot product category, so the British nod is quite a justifiable stock mover.
